T. Rowe Price QM U.S. Bond ETF (TAGG)
- Previous Close
41.03 - Open
41.16 - Bid 41.07 x 800
- Ask 41.17 x 1000
- Day's Range
41.06 - 41.23 - 52 Week Range
39.65 - 43.75 - Volume
5,418 - Avg. Volume
1,338 - Net Assets 90.86M
- NAV 41.12
- PE Ratio (TTM) 1.87
- Yield 3.90%
- YTD Daily Total Return -2.91%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.08%
Under normal conditions, the fund will invest at least 80% of its net assets in U.S. bonds. The fund’s overall investment strategy is to provide total returns that exceed the total returns of its benchmark index, the Bloomberg U.S. Aggregate Bond Index. The index is a broadly diversified index that typically consists of investment-grade, fixed income instruments with intermediate- to long-term maturities. The adviser generally invests in a wide range of bonds represented in the index.
T. Rowe Price
Fund Family
Intermediate Core Bond
Fund Category
90.86M
Net Assets
2021-09-28
Inception Date
Performance Overview: TAGG
Trailing returns as of 4/26/2024. Category is Intermediate Core Bond.
People Also Watch
Holdings: TAGG
Sector Weightings
Related ETF News
Research Reports: TAGG
Analyst Report: Monster Beverage Corporation
Monster Beverage is a leader in the energy drink subsegment of the nonalcoholic beverage market, generating two thirds of revenue in the US and Canada. The well-known Monster trademark includes brands such as Monster Energy, Monster Ultra, Java Monster, and Juice Monster. The firm also owns other energy drink brands, such as Reign, NOS, Burn, and Mother, and brews and distributes beers and flavored malt beverages following the acquisition of a craft brewer in 2022. Monster controls branding and innovation but outsources beverage manufacturing and packaging to copackers and finished goods distribution to bottlers in the global Coca-Cola system (pursuant to a 20-year agreement inked in 2015). Coke is the largest shareholder of Monster with a 19.5% stake.
RatingPrice TargetAnalyst Report: Monster Beverage Corporation
Monster Beverage is a leader in the energy drink subsegment of the nonalcoholic beverage market, generating two thirds of revenue in the US and Canada. The well-known Monster trademark includes brands such as Monster Energy, Monster Ultra, Java Monster, and Juice Monster. The firm also owns other energy drink brands, such as Reign, NOS, Burn, and Mother, and brews and distributes beers and flavored malt beverages following the acquisition of a craft brewer in 2022. Monster controls branding and innovation but outsources beverage manufacturing and packaging to copackers and finished goods distribution to bottlers in the global Coca-Cola system (pursuant to a 20-year agreement inked in 2015). Coke is the largest shareholder of Monster with a 19.5% stake.
RatingPrice TargetAnalyst Report: PepsiCo, Inc.
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay’s, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy offerings. Convenience foods account for approximately 55% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the United States and overseas. International markets make up 40% of total sales and one third of operating profits.
RatingPrice TargetAnalyst Report: CRISPR Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target